Associated Papers
Concurrent EGFR L858R and K860I mutations: PCR-negative but NGS-positive alterations that respond to EGFR inhibitors in non-small cell lung cancer.
Shi H et al.
Journal of Thoracic Disease, 2025
Rare mutation-dominant compound EGFR-positive NSCLC is associated with enriched kinase domain-resided variants of uncertain significance and poor clinical outcomes.
Zhao W et al.
Bmc Medicine, 2023
36829178 (PubMed )
Supplement: 12916_2023_2768_MOESM1_ESM.docx
Mutation Spectrum of EGFR From 21,324 Chinese Patients With Non-Small Cell Lung Cancer (NSCLC) Successfully Tested by Multiple Methods in a CAP-Accredited Laboratory.
Mao L et al.
Pathology Oncology Research : Por, 2021
Co-occurring genetic alterations and primary EGFR T790M mutations detected by NGS in pre-TKI-treated NSCLCs.
Tang Y et al.
Journal of Cancer Research and Clinical Oncology, 2020
Epidermal growth factor receptor somatic mutation analysis in 354 Chinese patients with non-small cell lung cancer.
Quan X et al.
Oncology Letters, 2018
[Experience on epidermal growth factor receptor gene mutation analysis in non-small cell lung cancer].
Zhang J et al.
Zhonghua Bing Li Xue Za Zhi = Chinese Journal of Pathology, 2011
Select a paper to view details